Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial
HemaSphere · 2026-05 · 10 (5)
DOI: 10.1002/hem3.70375 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 30.04.2026. Verfasst von Francesca Cordero und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science University of Turin Torino Italy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent clinical trials have underscored the value of repeated minimal residual disease (MRD) measurements as a highly sensitive method for detecting subclinical disease and enabling dynamic risk stratification in hematologic malignancies. Despite its clinical potential, the complex and heterogeneous nature of MRD kinetics presents significant challenges for interpreting and integrating it into routine clinical decision‐making. In this study, we present a comprehensive, model‐based workflow for the longitudinal analysis of MRD trajectories designed to improve relapse risk prediction. We applied this newly developed workflow to a cohort of patients with mantle cell lymphoma (MCL). MRD measurements were collected from both bone marrow (BM) and peripheral blood (PB) over time, stored in the Fondazione Italiana Linfomi MCL0208 clinical trial. Using our functional MRD workflow, we defined four MRD dynamics that collapsed into two clinically relevant groups: favorable (rapid, sustained negativization) and unfavorable (persistent or fluctuating MRD). Patients with unfavorable profiles showed significantly shorter time to progression (TTP), with hazard ratio (HR) = 4.18 (95% CI: 2.44–7.14) in BM and HR = 5.71 (95% CI: 2.86–11.42) in PB. External validation in the European MCL Network “Younger trial” confirmed the predictive power of this stratification, with Kaplan–Meier analyses demonstrating significant prognostic discrimination. The most informative temporal windows for patient clustering vary by tissue. Early‐phase BM assessments offer greater discriminatory power, whereas late‐phase assessments are most informative in PB. These findings indicate that longitudinal MRD assessment in PB represents a clinically actionable strategy that could reduce dependence on invasive BM procedures.
Autor:innen und Institutionen
- Department of Computer Science University of Turin Torino Italy.
- Hematology Division, Department of Molecular Biotechnologies and Health Sciences University of Turin Torino Italy.
- Hematology Unit Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino" Torino Italy.
- Department of Mathematics "G. Peano" University of Turin Torino Italy.
- Unit of Clinical Epidemiology Azienda Ospedaliera Universitaria Città della Salute e della Scienza and CPO Piemonte Torino Italy.
- Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy.
ORCID-Profile: Francesca Cordero, Simone Ragaini, Federica Cavallo, Vittorio Ruggero Zilioli, Luca Arcaini, Elizabeth Macintyre
Zitieren
APA
Cordero, F., Ferrero, S., Pernice, S., Genuardi, E., Volpatto, D., Sirovich, R., Civita, A. M., Evangelista, A., Ragaini, S., Di Rocco, A., Re, A., Stefoni, V., Cavallo, F., Boccomini, C., Balzarotti, M., Zilioli, V. R., Gomes da Silva, M., Arcaini, L., Celli, M., …, & Ladetto, M. (2026). Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial. HemaSphere, 10(5). https://doi.org/10.1002/hem3.70375
Vancouver
Cordero F, Ferrero S, Pernice S, Genuardi E, Volpatto D, Sirovich R, et al. Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial. HemaSphere. 2026;10(5). doi:10.1002/hem3.70375
BibTeX
@article{Cordero2026,
author = {Cordero, Francesca and Ferrero, Simone and Pernice, Simone and Genuardi, Elisa and Volpatto, Daniela and Sirovich, Roberta and Civita, Aurora Maria and Evangelista, Andrea and Ragaini, Simone and Di Rocco, Alice and Re, Alessandro and Stefoni, Vittorio and Cavallo, Federica and Boccomini, Carola and Balzarotti, Monica and Zilioli, Vittorio Ruggero and Gomes da Silva, Maria and Arcaini, Luca and Celli, Melania and Zaccaria, Gian Maria and Tortarolo, Dora and Beccuti, Marco and Hoster, Eva and Pott, Christiane and Macintyre, Elizabeth and Hermine, Olivier and Dreyling, Martin and Ladetto, Marco},
title = {Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {5},
doi = {10.1002/hem3.70375}
}
EUVIMED